Comprehensive genomic profiling testing in Japanese castration-resistant prostate cancer patients: results of a single-center retrospective cohort study

被引：1

作者：

Fukushima, Takafumi ^{[1
]}

Goto, Keisuke ^{[1
]}

Hayashi, Tetsutaro ^{[1
]}

Ikeda, Kenichiro ^{[1
]}

Hatayama, Tomoya ^{[1
]}

Yamanaka, Ryoken ^{[1
]}

Iwane, Kyosuke ^{[1
]}

Tasaka, Ryo ^{[1
]}

Kohada, Yuki ^{[1
]}

Takemoto, Kenshiro ^{[1
]}

Kobatake, Kohei ^{[1
]}

Goriki, Akihiro ^{[1
]}

Toshida, Asuka ^{[2
]}

Nakahara, Hikaru ^{[2
]}

Motonaga, Masanori ^{[3
]}

Tokumo, Kentaro ^{[4
]}

Fujii, Yasutoshi ^{[4
,5
]}

Hayes, C. Nelson ^{[5
]}

Okamoto, Wataru ^{[6
]}

Kubo, Toshio ^{[7
]}

Matsumoto, Takashi ^{[8
]}

Shiota, Masaki ^{[8
]}

Yamamoto, Noboru ^{[9
]}

Urabe, Yuji ^{[10
]}

Hiyama, Eiso ^{[11
,12
]}

Arihiro, Koji ^{[13
]}

Hinoi, Takao ^{[2
]}

Hinata, Nobuyuki ^{[1
]}

机构：

[1] Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Dept Urol, 1-2-3 Kasumi,Minamiku, Hiroshima 7348551, Japan

[2] Hiroshima Univ Hosp, Genom Med Ctr, Dept Clin & Mol Genet, Hiroshima, Japan

[3] Hiroshima Univ Hosp, Dept Pharmaceut Serv, Hiroshima, Japan

[4] Hiroshima Univ Hosp, Dept Clin Oncol, Hiroshima, Japan

[5] Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Dept Gastroenterol, Hiroshima, Japan

[6] Hiroshima Univ Hosp, Canc Treatment Ctr, Hiroshima, Japan

[7] OkayamaUnivers Hosp, Ctr Clin Oncol, Okayama, Japan

[8] Kyushu Univ, Grad Sch Med Sci, Dept Urol, Fukuoka, Japan

[9] Natl Canc Ctr, Dept Expt Therapeut, Tokyo, Japan

[10] Hiroshima Univ Hosp, Dept Gastrointestinal Endoscopy & Med, Hiroshima, Japan

[11] Hiroshima Univ Hosp, Dept Pediat Surg, Hiroshima, Japan

[12] Hiroshima Univ, Nat Sci Ctr Basic Res & Dev, Hiroshima, Japan

[13] Hiroshima Univ Hosp, Dept AnatomicalPathol, Hiroshima, Japan

来源：

JAPANESE JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 54卷 / 02期

关键词：

castration-resistant prostate cancer; comprehensive genome profiling testing; next-generation sequencing; CDK12; chemotherapy; POSITIVE SOLID TUMORS; INCREASED SURVIVAL; DOCETAXEL; PREDNISOLONE; MITOXANTRONE; ABIRATERONE;

D O I：

10.1093/jjco/hyad148

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Objective Comprehensive genomic profiling testing using a hybrid-capture next-generation sequencing is commonly used in clinical practice to employ precision medicine in cancer treatment worldwide. In this study, we aimed to analyze the profiles obtained using comprehensive genomic profiling testing that was performed in Japanese castration-resistant prostate cancer patients and to discuss the genetic findings in a real-world setting.Methods A total of 60 cases and 57 castration-resistant prostate cancer patients underwent comprehensive genomic profiling testing between 1 January 2021 and 31 December 2022. Four types of comprehensive genomic profiling testing were selected, and clinically significant cancer-specific gene alterations were identified.Results The median age of patients was 74 years, and the median prostate-specific antigen value at the time of submission was 18.6 ng/ml. Fifty-seven (95%) of 60 cases were metastatic castration-resistant prostate cancers, and 3 cases (5%) were non-metastatic. Among all genetic alterations, androgen-receptor alteration was the most frequently detected in 17 cases (28.3%), followed by 15 cases of TP53 (25.0%), 14 cases of CDK12 (23.3%), 10 cases of phosphatase and tensin homolog (16.7%) and 9 cases of ATM (15.0%) mutations. A total of 13 patients (21.7%) received systemic therapy according to the comprehensive genomic profiling testing results. Overall, the survival rate was significantly greater in the group treated through systemic therapy based on comprehensive genomic profiling testing compared with the group without new therapeutic treatment (P = 0.041).Conclusions Comprehensive genomic profiling testing is recommended in castration-resistant prostate cancer patients identified as resistant to standard therapy as this can provide a new therapeutic option. Comprehensive genomic profiling testing is useful for the selection of treatment for Japanese patients with castration-resistant prostate cancer.

引用

页码：175 / 181

页数：7

共 50 条

[41] Efficacy of S-1 in Patients with Castration-Resistant Prostate Cancer: A Phase II Study
Akaza, Hideyuki
Ikemoto, Isao
Namiki, Mikio
Usami, Michiyuki
Kobayashi, Mikio
Fujimoto, Hiroyuki
Tsukamoto, Taiji
Naito, Seiji
ONCOLOGY, 2010, 78 (5-6) : 323 - 328
[42] Japanese phase I study of cabazitaxel in metastatic castration-resistant prostate cancer
Nozawa, Masahiro
Mukai, Hirofumi
Takahashi, Shunji
Uemura, Hiroji
Kosaka, Takeo
Onozawa, Yusuke
Miyazaki, Jun
Suzuki, Kazuhiro
Okihara, Koji
Arai, Yoichi
Kamba, Tomomi
Kato, Masashi
Nakai, Yasutomo
Furuse, Hiroshi
Kume, Haruki
Ide, Hisamitsu
Kitamura, Hiroshi
Yokomizo, Akira
Kimura, Takahiro
Tomita, Yoshihiko
Ohno, Keiji
Kakehi, Yoshiyuki
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2015, 20 (05) : 1026 - 1034
[43] Docetaxel reintroduction in patients with metastatic castration-resistant docetaxel-sensitive prostate cancer: a retrospective multicentre study
Eymard, Jean-Christophe
Oudard, Stephane
Gravis, Gwenaelle
Ferrero, Jean-Marc
Theodore, Christine
Joly, Florence
Priou, Frank
Krakowski, Ivan
Zannetti, Alain
Thill, Laurence
Beuzeboc, Philippe
BJU INTERNATIONAL, 2010, 106 (07) : 974 - 978
[44] The Effect of Treatment Sequence on Overall Survival for Men With Metastatic Castration-resistant Prostate Cancer: A Multicenter Retrospective Study
Okita, Kazutaka
Hatakeyama, Shingo
Narita, Shintaro
Takahashi, Masahiro
Sakurai, Toshihiko
Kawamura, Sadafumi
Hoshi, Senji
Ishida, Masanori
Kawaguchi, Toshiaki
Ishidoya, Shigeto
Shimoda, Jiro
Sato, Hiromi
Mitsuzuka, Koji
Ito, Akihiro
Tsuchiya, Norihiko
Arai, Yoichi
Habuchi, Tomonori
Ohyama, Chikara
CLINICAL GENITOURINARY CANCER, 2020, 18 (02) : E103 - E111
[45] Cabazitaxel in patients aged ≥80 years with castration-resistant prostate cancer: Results of a post-marketing surveillance study in Japan
Matsubara, Nobuaki
Suzuki, Kazuhiro
Kazama, Hirotaka
Tsukube, Shoko
Seto, Takeshi
Matsuyama, Hideyasu
JOURNAL OF GERIATRIC ONCOLOGY, 2020, 11 (07) : 1067 - 1073
[46] Comparing Sequencing of Abiraterone and Enzalutamide in Men With Metastatic Castration-Resistant Prostate Cancer: A Retrospective Study
Maughan, Benjamin L.
Luber, Brandon
Nadal, Rosa
Antonarakis, Emmanuel S.
PROSTATE, 2017, 77 (01): : 33 - 40
[47] Preliminary Efficacy, Tolerability, and Safety Analysis of Darolutamide for Metastatic Castration-Resistant Prostate Cancer: A Single-Center, Open-Label Study
Yu, JunJie
Zhou, KaiChen
Wang, JunQi
Mao, LiJun
UROLOGIA INTERNATIONALIS, 2024,
[48] Efficacy of cabazitaxel and the influence of clinical factors on the overall survival of patients with castration-resistant prostate cancer: A local experience of a multicenter retrospective study
Takai, Manabu
Kato, Seiichi
Nakano, Masahiro
Fujimoto, Shota
Iinuma, Koji
Ishida, Takashi
Taniguchi, Mitsuhiro
Tamaki, Masayoshi
Uno, Masahiro
Takahashi, Yoshito
Komeda, Hisao
Koie, Takuya
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2021, 17 (03) : 238 - 244
[49] Weekly low-dose docetaxel combined with estramustine and dexamethasone for Japanese patients with metastatic castration-resistant prostate cancer
Koji Hatano
Kazuo Nishimura
Yasutomo Nakai
Takahiro Yoshida
Mototaka Sato
Atsunari Kawashima
Masatoshi Mukai
Akira Nagahara
Motohide Uemura
Daizo Oka
Masashi Nakayama
Hitoshi Takayama
Kiyonori Shimizu
Norio Meguro
Tsuyoshi Tanigawa
Seiji Yamaguchi
Akira Tsujimura
Norio Nonomura
International Journal of Clinical Oncology, 2013, 18 : 704 - 710
[50] Weekly low-dose docetaxel combined with estramustine and dexamethasone for Japanese patients with metastatic castration-resistant prostate cancer
Hatano, Koji
Nishimura, Kazuo
Nakai, Yasutomo
Yoshida, Takahiro
Sato, Mototaka
Kawashima, Atsunari
Mukai, Masatoshi
Nagahara, Akira
Uemura, Motohide
Oka, Daizo
Nakayama, Masashi
Takayama, Hitoshi
Shimizu, Kiyonori
Meguro, Norio
Tanigawa, Tsuyoshi
Yamaguchi, Seiji
Tsujimura, Akira
Nonomura, Norio
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2013, 18 (04) : 704 - 710

← 1 2 3 4 5 →